From a therapeutic perspective, we did observe that the dual small molecule inhibitor of FADS1 and FADS2, CP-24879 displayed varying antileukemia activity on PD-AML samples without significantly harming healthy BM-derived hematopoietic cells. This evidence concerns the gene FADS1 and acute myeloid leukemia.